drugset / Trial / NCT04497883

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

NCT04497883

Phase 1 Completed 24 enrolled Shire
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics (PK), safety, and tolerability of maribavir administered as a single oral dose in healthy, adult participants of Japanese descent and matched, healthy, adult, non-Hispanic, Caucasian participants. In addition, this study will assess the dose-proportionality of PK of maribavir in healthy, adult participants of Japanese descent.

Timeline

Start
2020-08-07
Primary completion
2020-11-12
Completion
2020-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Maribavir Small molecule 200 mg Oral
Subject Maribavir Small molecule 400 mg Oral
Subject Maribavir Small molecule 800 mg Oral

Indications

No indication recorded.